Stay updated with breaking news from Immunopharma Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers have shown that a novel antibody generated to target an 'essential amino acid sequence’ of both interleukin-17A and F has greater activity and potentially fewer side effects than existing biological therapies for conditions such as as rhe
/PRNewswire/ -- University of Birmingham Enterprise Ltd, 15 August 2023: Research has shown that a novel antibody generated to target an 'essential amino acid...
Researchers have shown that a novel antibody generated to target an 'essential amino acid sequence' of both interleukin-17A and F has greater activity and potentially fewer side effects than existing biological therapies for conditions such as as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).